NEW YORK (GenomeWeb News) – Geron and Exeter Life Sciences said today that Start Licensing, a joint venture between the two firms, and ViaGen, a subsidiary of Exeter, have merged to form a new entity that will focus on animal cloning.
 
Start manages and licenses a portfolio of intellectual property rights related to animal reproductive technologies, including nuclear transfer cloning technology that was developed at the Roslin Foundation to clone Dolly the sheep. ViaGen is an animal genomics and livestock cloning firm.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has approved Kite Pharmaceuticals' CAR T-cell therapy for large B-cell lymphomas, the New York Times reports.

Kaiser Health News reports that gene therapies could cost more than a million dollars.

Worcester Polytechnic Institute researchers have received a grant to combine biology and computer science for high school students.

In Nature this week: variants associated with obsessive-compulsive disorder, review of key CRISPR enzymes, and more.